PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsPharmaEssentia
PharmaEssentia
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
BesremiRopeginterferon alfa-2b2021-11-12
Polycythemia vera
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Ropeginterferon alfa-2b
hepatitis b
,
chronic hepatitis
,
healthy volunteers/patients
,
chronic hepatitis d
,
hepatitis
,
hepatitis a
,
hepatitis d
,
coinfection
,
carcinoma
,
hepatocellular carcinoma
,
liver neoplasms
,
chronic hepatitis b
,
hepatitis c
,
chronic hepatitis c
,
infections
,
communicable diseases
,
essential thrombocythemia
,
thrombocytosis
,
primary myelofibrosis
,
polycythemia vera
,
polycythemia
,
myeloproliferative disorders
,
herpesviridae infections
Benzocaine
covid-19
,
enterovirus
,
rhinovirus
,
enterovirus infections
Calcium carbonate
metabolic bone diseases
,
menopause
Albumin
overactive urinary bladder
,
urinary incontinence
,
urinary bladder diseases
,
enuresis
,
aging
Tenofovir
heart disease risk factors
,
metabolic diseases
,
lipid metabolism disorders
,
healthy volunteers/patients
,
renal insufficiency
,
viremia
,
biliary liver cirrhosis
,
cholangitis
,
tuberculosis
,
hiv-1
,
hiv-2
,
breast feeding
,
pregnancy
,
antibiotic prophylaxis
,
virus diseases
,
obesity
,
metabolic syndrome
,
body weight changes
,
fasting
,
hiv infections
,
hiv
,
acquired immunodeficiency syndrome
,
infections
,
communicable diseases
,
immunologic deficiency syndromes
,
hepatitis b
,
hepatitis
,
hepatitis a
,
body weight
,
chronic hepatitis b
,
persistent infection
,
weight gain
,
sarcoma
,
kaposi sarcoma
,
immunosuppression therapy
,
cardiovascular diseases
,
chronic hepatitis
,
metabolic bone diseases
,
osteoporosis
,
neurotoxicity syndromes
,
neurocognitive disorders
,
hepatitis c
,
coinfection
,
chemical and drug induced liver injury
,
proteinuria
,
hiv seropositivity
,
aging
Albinterferon alfa-2b
chronic hepatitis b
,
chronic hepatitis
,
hepatitis c
,
chronic hepatitis c
,
hepatitis
,
hepatitis a
Fendrix
diarrhea
,
falciparum malaria
,
job syndrome
,
hiv infections
,
acquired immunodeficiency syndrome
,
immunologic deficiency syndromes
,
meningococcal infections
,
malaria
,
streptococcal infections
,
pneumonia
,
papillomavirus infections
,
herpesviridae infections
,
meningitis
,
otitis media
,
otitis
,
virus diseases
,
pneumococcal pneumonia
,
streptococcus pneumoniae
,
meningococcal meningitis
,
infections
,
hiv
,
papillomavirus vaccines
,
hematopoietic stem cell transplantation
,
hepatitis b
,
hepatitis
,
hepatitis a
,
chronic hepatitis b
,
chronic hepatitis
,
diphtheria
,
tetanus
,
haemophilus influenzae type b
,
whooping cough
,
poliomyelitis
,
human influenza
,
tetany
,
fibrosis
,
diabetes mellitus
,
rotavirus infections
,
liver cirrhosis
,
type 2 diabetes mellitus
,
healthy volunteers/patients
,
immunologic tests
,
liver diseases
,
non-alcoholic fatty liver disease
,
fatty liver
,
pneumococcal infections
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use